Neurosterix Closes $105 Million Series B

Company Neurosterix; Addex Therapeutics Event Type Series B financing ($105 million) Modality Small molecule (oral M4 positive allosteric modulator) Asset NTX-253 Target Muscarinic M4 receptor Disease Area Schizophrenia Summary Addex disclosed November 11 that its 2024 spinout Neurosterix closed a $105 million Series B to…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *